Prof. Dr. Schulz, Martin

Geschäftsführer Pharmazie, Deutsches Arzneiprüfungsinstitut e. V. (DAPI), Berlin

seit Januar 2009

Vorsitzender der Arzneimittelkommission der Deutschen Apotheker (AMK)

seit April 2008

Geschäftsführer für den Bereich Arzneimittel der ABDA, der BAK und des DAV

seit Juli 2005

Honorarprofessor der Goethe-Universität Frankfurt

seit März 2002

Zusätzlich: Geschäftsführer Pharmazie des Deutschen Arzneiprüfungsinstituts (DAPI)

2001 - 2005

Lehrauftrag Klinische Pharmazie an der Goethe-Universität Frankfurt

1993

Fachapotheker für Arzneimittelinformation

1992 - 2008

Stellvertretender Vorsitzender der Arzneimittelkommission der Deutschen Apotheker (AMK)

1989

Fachpharmakologe DGPT

Oktober 1988 - März 2008

Leiter Zentrum für Arzneimittelinformation und Pharmazeutische Praxis (ZAPP) der ABDA

1988

Promotion in Pharmakologie zum Dr. rer. nat.

Oktober 1984 - September 1988

Wissenschaftlicher Mitarbeiter am Pharmakologischen Institut und Institut für Rechtsmedizin, Universität Hamburg

1984 - 1986

Studium der Medizin (Universität Hamburg)

1983 - 1984

Apotheker, Krankenhaus St. Adolf-Stift, Reinbek

Mai 1983

Approbation als Apotheker

1978 - 1982

Studium der Pharmazie (Universität Hamburg)

Publications:

Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Fixkombinationen von ACE-Hemmern, Angiotensin-II-Rezeptorblockern, Betablockern, Calciumkanalblockern und Diuretika - Stand 15.06.2023

Increased Demand for Pharmaceutical Drugs Containing Potassium Iodide In Connection with the Russia-Ukraine Conflict

Assessment of the Prescriptions of Systemic Antibiotics in Primary Dental Care in Germany from 2017 to 2021: A Longitudinal Drug Utilization Study

Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021

Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia

Verordnungsqualität oraler Fluorchinolone in den deutschen Bundesländern 2014 bis 2019

Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave

Infliximab And Etanercept Biosimilars And Originators: Learnings From Regional Market Dynamics In Germany

Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV Infektion

Changes in utilization of antihypertensive drugs following angiotensin receptor blocker product recalls in Germany

Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014–2019

Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave

Differences In Persistence Rates Between Various Classes Of Antihypertensives In Diabetic Patients

The Value of Access to Pharmacy Claims Data for Healthcare Market Analyses

Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

DAPI-Zahlen aus Berlin. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken

Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study.

Switching the pharmaceutical dosage form of extended-release valproate is associated with therapeutic modification of antiepileptic therapy

Effect of switching branded risedronate to branded or generic alendronate on medication compliance with weekly bisphosphonates: a cohort study utilizing the dapi prescription claims database

Medication persistence with ginkgo biloba drugs of different dosage strengths - Persistenz bei Ginkgo biloba-Arzneimitteln unterschiedlicher Wirkstärke.

Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany

Innovative Arzneimittel bei Hepatitis C - Was kostet der Zusatznutzen?

Rebate contracts: reasons not to substitute

Innovative Hepatitis-C-Arzneimittel - Was der Zusatznutzen wirklich kostet

Rabattverträge nach § 130a Abs. 8 SGB V: Das Instrument der pharmazeutischen Bedenken

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study

Hepatitis C - Neue Wirkstoffe im Vergleich

Ad hoc-Auswertungen des DAPI. Dokumentation pharmazeutischer Bedenken in Berlin

DAPI-Zahlen aus Rheinland-Pfalz. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken

Zielpreise für Leitsubstanzen: Verantwortungsteilung zwischen Arzt und Apotheker

Pharmazeutische Bedenken. Die zehn häufigsten Wirkstoffe in Niedersachsen.

Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients

Can claims data help validating drug risk signals? A case report

Evaluation of pharmaceutical concerns in Germany: frequency and potential reasons

Adherence to antihypertensives: feasibility of two self-report instruments to investigate medication-taking behaviour in German community pharmacies.

Temporal synchrony between drug dispensings and adverse drug events? The example of statins & rhabdomyolysis and metamizole or clozapine & agranulocytosis

Oral Antibiotics in Germany and the Netherlands in Primary Care from 2012 – 2016: A Comparison

In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.

Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016

Post-mortem analysis of prescription opioids - A follow-up examination by LC–MS/MS with focus on fentanyl

The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.

Versorgungsforschung: Persistenz und Compliance bei Antihypertensiva

Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib

Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database

Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.

Comparison of different ways of calculation (DDD vs. SPC) to determine persistence and compliance with beta blockers in the DAPI database.

Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.

Association between generic substitution of valproate and therapeutic modification of antiepileptic therapy – a cohort study with time-dependent exposure utilizing the DAPI ambulatory drug claims data

Strategien zur Verbesserung der Einnahmetreue von Medikamenten.

Verbesserung der Therapietreue bei Hypertonikern - eine Aufgabe für den Apotheker

Statine – Verordnungsanalyse und Praxistipps

Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals

Arzneimittelversorgung – Coxibverordnungen nach Marktrücknahmen und Risikomeldungen

Epidemiologische Analyse der Compliance

Impact of rebate contract legislation on generic substitution of valproate – a retrospective study of ambulatory drug dispensing in the DAPI database

Impact of risk communications and market withdrawals on prescribing of cyclooxygenase-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs

Aktuelle Verordnungen von COX-2-Hemmern in Deutschland

Persistence under treatment with ramipril

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?

Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.

Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.

Pharmacy refill adherence with antidepressants.

Utilizing claims data to assess persistence with antidepressants.

Non-Compliance – das unterschätzte Problem: Neue Möglichkeiten der Erfassung über Datenbankanalysen

Methoden der Datenbank-basierten Persistenz- und Apotheken-basierten Adhärenz-Erfassung am Beispiel von Antihypertensiva

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

“Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription